Bicara Therapeutics Raises $150M to Advance Novel Cancer Therapy

BOSTON, MA – February 24, 2026 – Bicara Therapeutics Inc. has successfully priced a significant public offering expected to raise approximately $150 million in gross proceeds, a strategic capital infusion designed to propel its lead cancer drug, ficerafusp alfa, through late-stage development and toward a potential U.S. market launch.

The clinical-stage biopharmaceutical company (Nasdaq: BCAX) announced the underwritten offering consists of 7,175,000 shares of its common stock at $16.00 per share, alongside 2,200,000 pre-funded warrants for certain investors. The move, managed by a syndicate of prominent banks including Morgan Stanley, TD Cowen, and BofA Securities, signals strong investor confidence in Bicara’s innovative approach to treating solid tumors.

This financing is critical as Bicara prepares for the final and most capital-intensive phases of drug development for ficerafusp alfa, a first-in-class therapy that has already shown considerable promise in treating advanced head and neck squamous cell carcinoma (HNSCC).

Fueling a Late-Stage Clinical Push

The net proceeds from the offering are earmarked for a multi-pronged strategy centered entirely on ficerafusp alfa. A primary objective is to build out the medical and commercial infrastructure necessary to support a planned regulatory filing with the U.S. Food and Drug Administration (FDA) and a subsequent commercial launch, should the drug receive approval. This involves preparing for sales, marketing, and medical affairs activities, which are crucial for bringing a new therapy to patients.

Furthermore, the capital will accelerate the ongoing development of ficerafusp alfa in its lead indication: first-line treatment for patients with recurrent or metastatic (R/M) HPV-negative HNSCC. A key part of this accelerated development includes further investigation into a less frequent dosing schedule. Early data has suggested that an every-other-week or even every-three-week regimen could be viable, a significant potential improvement for patient convenience and quality of life compared to more frequent infusions. The funds will also cover substantial manufacturing costs for the drug to supply ongoing and future clinical trials and support early-stage studies to identify other cancer types where ficerafusp alfa might be effective.

A New Frontier in Head and Neck Cancer Treatment

Ficerafusp alfa (also known as BCA101) represents a novel approach in oncology. It is a bifunctional antibody, meaning it is engineered to bind to two separate targets simultaneously: the epidermal growth factor receptor (EGFR), a well-known driver of cancer cell growth, and transforming growth factor-beta (TGF-β), a protein that creates a protective, fibrous shield around tumors and suppresses the immune system.

By targeting both, ficerafusp alfa is designed to dismantle this protective tumor microenvironment, enabling immune cells to penetrate and attack the cancer more effectively. This unique mechanism has yielded impressive results in clinical trials, particularly when combined with the immune checkpoint inhibitor pembrolizumab.

In October 2025, the FDA granted the combination therapy Breakthrough Therapy Designation for first-line R/M HPV-negative HNSCC, a status reserved for drugs that demonstrate substantial improvement over available therapies for serious conditions. This designation was supported by Phase 1b data showing a 64% overall response rate (ORR) and an 18% complete response (CR) rate—meaning all signs of cancer disappeared in some patients. These results stand in stark contrast to the historical 19% ORR for pembrolizumab used alone in this patient population.

More recent data from early 2026 on a less-frequent 2000mg every-other-week dose continued to show strong efficacy with a 48% confirmed ORR and an even higher 26% CR rate, bolstering the case for a more convenient treatment regimen. The drug is currently being studied in a global, pivotal Phase 2/3 trial, with enrollment expected to be completed by the end of 2026 and an interim analysis planned for mid-2027.

Navigating a Discerning Biotech Market

Bicara’s successful capital raise comes at a time when the biopharmaceutical fundraising market, while recovering from a post-pandemic slump, remains highly selective. Investors are increasingly prioritizing companies with validated science, strong clinical data, and a clear path to market. Bicara’s ability to secure $150 million in this environment serves as a powerful market barometer, indicating a high degree of confidence in its lead asset.

The market potential for a new, effective HNSCC treatment is substantial. The global market for HNSCC therapies was valued at over $2.3 billion in 2025 and is projected to more than double to over $5.4 billion by 2035. This growth is driven by the rising incidence of head and neck cancers and the pressing unmet need for better treatments, especially for HPV-negative patients who often have poorer prognoses.

By securing this funding, Bicara has positioned itself to capitalize on this opportunity, armed with a drug candidate that has the potential to become a new standard of care.

Bolstering Financials for the Road Ahead

The offering significantly strengthens Bicara's financial position. The company ended 2025 with approximately $414.8 million in cash and investments, which it had projected would fund operations into the first half of 2029. The addition of the proceeds from this offering extends that runway considerably, providing the company with the resources to navigate the costly late stages of clinical development, regulatory submission, and initial commercialization without near-term financial constraints.

This financial fortification is timely, as the company’s research and development expenses have been increasing, a natural consequence of running a large, global pivotal trial. The new capital de-risks the company’s ambitious development plan and provides a clear path forward to execute its strategy and potentially deliver a transformative new medicine to cancer patients. With its finances secured and a promising drug in a pivotal trial, Bicara is now well-equipped for the critical milestones that lie ahead.